Given this increased risk of infections, clinicians also prescribe broad-spectrum antibiotics to patients hospitalized with cirrhosis without infection to prevent hospital-acquired infections (HAI) and subsequent sepsis, as we observed in the Albumin to Prevent Infection in Chronic Liver Failure (ATTIRE) trial with 50% receiving antibiotics at trial entry, although only 27% were diagnosed with infection (5). The gene discussed is ALB; the disease is nosocomial infection.